vs
Shoals Technologies Group, Inc.（SHLS）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Bio-Techne的季度营收约是Shoals Technologies Group, Inc.的2.2倍（$311.4M vs $140.6M），Bio-Techne净利率更高（16.4% vs -0.2%，领先16.6%），Shoals Technologies Group, Inc.同比增速更快（74.9% vs -1.5%），过去两年Shoals Technologies Group, Inc.的营收复合增速更高（19.0% vs 1.3%）
Shoals科技集团是可再生能源及电动出行领域的电气系统平衡解决方案供应商，核心产品覆盖光伏、储能及充电桩用连接组件，主要服务北美、欧洲、亚太市场的公用事业、工商业及民用客户。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
SHLS vs TECH — 直观对比
营收规模更大
TECH
是对方的2.2倍
$140.6M
营收增速更快
SHLS
高出76.4%
-1.5%
净利率更高
TECH
高出16.6%
-0.2%
两年增速更快
SHLS
近两年复合增速
1.3%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $140.6M | $311.4M |
| 净利润 | $-297.0K | $51.0M |
| 毛利率 | 29.2% | 66.9% |
| 营业利润率 | 5.5% | 24.2% |
| 净利率 | -0.2% | 16.4% |
| 营收同比 | 74.9% | -1.5% |
| 净利润同比 | -5.3% | 126.0% |
| 每股收益（稀释后） | $0.00 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SHLSTECH
| Q1 26 | $140.6M | $311.4M | ||
| Q4 25 | $148.3M | $295.9M | ||
| Q3 25 | $135.8M | — | ||
| Q2 25 | $110.8M | $317.0M | ||
| Q1 25 | $80.4M | $316.2M | ||
| Q4 24 | $107.0M | $297.0M | ||
| Q3 24 | $102.2M | $289.5M | ||
| Q2 24 | $99.2M | $306.1M |
净利润SHLSTECH
| Q1 26 | $-297.0K | $51.0M | ||
| Q4 25 | $8.1M | $38.0M | ||
| Q3 25 | $11.9M | — | ||
| Q2 25 | $13.9M | $-17.7M | ||
| Q1 25 | $-282.0K | $22.6M | ||
| Q4 24 | $7.8M | $34.9M | ||
| Q3 24 | $-267.0K | $33.6M | ||
| Q2 24 | $11.8M | $40.6M |
毛利率SHLSTECH
| Q1 26 | 29.2% | 66.9% | ||
| Q4 25 | 31.6% | 64.6% | ||
| Q3 25 | 37.0% | — | ||
| Q2 25 | 37.2% | 62.7% | ||
| Q1 25 | 35.0% | 67.9% | ||
| Q4 24 | 37.6% | 65.3% | ||
| Q3 24 | 24.8% | 63.2% | ||
| Q2 24 | 40.3% | 66.4% |
营业利润率SHLSTECH
| Q1 26 | 5.5% | 24.2% | ||
| Q4 25 | 11.7% | 18.4% | ||
| Q3 25 | 13.7% | — | ||
| Q2 25 | 14.4% | -7.5% | ||
| Q1 25 | 5.4% | 12.2% | ||
| Q4 24 | 15.4% | 16.0% | ||
| Q3 24 | 4.4% | 13.8% | ||
| Q2 24 | 18.7% | 15.0% |
净利率SHLSTECH
| Q1 26 | -0.2% | 16.4% | ||
| Q4 25 | 5.5% | 12.8% | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | 12.5% | -5.6% | ||
| Q1 25 | -0.4% | 7.1% | ||
| Q4 24 | 7.3% | 11.7% | ||
| Q3 24 | -0.3% | 11.6% | ||
| Q2 24 | 11.9% | 13.3% |
每股收益（稀释后）SHLSTECH
| Q1 26 | $0.00 | $0.32 | ||
| Q4 25 | $0.05 | $0.24 | ||
| Q3 25 | $0.07 | — | ||
| Q2 25 | $0.08 | $-0.11 | ||
| Q1 25 | $0.00 | $0.14 | ||
| Q4 24 | $0.04 | $0.22 | ||
| Q3 24 | $0.00 | $0.21 | ||
| Q2 24 | $0.07 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.9M | $209.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $601.6M | $2.1B |
| 总资产 | $1.0B | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SHLSTECH
| Q1 26 | $1.9M | $209.8M | ||
| Q4 25 | $7.3M | $172.9M | ||
| Q3 25 | $8.6M | — | ||
| Q2 25 | $4.7M | $162.2M | ||
| Q1 25 | $35.6M | $140.7M | ||
| Q4 24 | $23.5M | $177.5M | ||
| Q3 24 | $11.1M | $187.5M | ||
| Q2 24 | $3.2M | $152.9M |
总债务SHLSTECH
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | $141.8M | $330.0M | ||
| Q4 24 | $141.8M | $300.0M | ||
| Q3 24 | $141.8M | $300.0M | ||
| Q2 24 | $146.8M | $319.0M |
股东权益SHLSTECH
| Q1 26 | $601.6M | $2.1B | ||
| Q4 25 | $600.0M | $2.0B | ||
| Q3 25 | $589.6M | — | ||
| Q2 25 | $575.4M | $1.9B | ||
| Q1 25 | $558.9M | $2.0B | ||
| Q4 24 | $556.8M | $2.1B | ||
| Q3 24 | $545.2M | $2.1B | ||
| Q2 24 | $544.6M | $2.1B |
总资产SHLSTECH
| Q1 26 | $1.0B | $2.6B | ||
| Q4 25 | $904.1M | $2.5B | ||
| Q3 25 | $851.8M | — | ||
| Q2 25 | $795.0M | $2.6B | ||
| Q1 25 | $788.4M | $2.6B | ||
| Q4 24 | $793.1M | $2.7B | ||
| Q3 24 | $801.3M | $2.7B | ||
| Q2 24 | $788.4M | $2.7B |
负债/权益比SHLSTECH
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | 0.25× | 0.16× | ||
| Q4 24 | 0.25× | 0.14× | ||
| Q3 24 | 0.26× | 0.14× | ||
| Q2 24 | 0.27× | 0.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SHLS
暂无分部数据
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
